Introduction
Analysis of the molecular basis of human tumors has provided evidence for the multistep pathogenesis 1 of many of these malignancies, including acute myelogenous leukemia (AML). However, it has been difficult to identify early mutations in AML, due in part to the rarity of pedigrees with an inherited predisposition to develop leukemias. In 1985, Dowton et al 2 reported on a large kindred with an autosomal dominant bone marrow disorder, consisting of qualitative and quantitative defects in platelet function and a propensity to develop AML. Of 29 affected family members, eight have developed AML or myelodysplastic syndrome (MDS). We have recently established linkage of this disorder to chromosome 21q22.1-22.2. 3 The nearest flanking markers, D21S1265 and D21S167 define the familial platelet disorder (FPD) critical region at a genetic distance of approximately 15.2 centimorgans and physical distance of approximately 6 megabases.
The placement of the FPD critical region on chromosome 21q22 is of particular interest as this locus has been previously implicated in AML and acute lymphoblastic leukemia (ALL) through the (8;21) , (3;21) and (12;21) chromosomal translocations. [4] [5] [6] As well, there is a potential association between the FPD gene and the hematologic abnormalities seen in Down syndrome (trisomy 21), including an approximate 15-fold increased risk of developing AML. 7, 8 As there is no discernible, constitutional cytogenetic abnormality in this pedigree, a positional cloning strategy has been undertaken to identify the mutant gene responsible for this phenotype. Several known candidate genes map to this locus, including CBFA2, 4 IFNAR1, 9 IFNAR2, 10 CRFB4, 11 GART, 12 SON, 13 KCNE1, 14 SCL5A3 15 and ATP50 (Antonarakis, personal communication). We have first undertaken mutation analysis of three of these candidate genes: CBFA2, IFNAR1 and CRFB4 for involvement in FPD.
CBFA2 (PEBP2␣A; AML1 3, 4, 6, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] encodes a subunit of the heterodimeric transcription factor polyomavirus enhancerbinding protein 2 (PEBP2), also known as core binding factor (CBF) and is involved in both DNA binding and proteinprotein interaction. 16, 23, 25 CBFA2 is the fusion partner on chromosome 21 involved in the t(8;21) translocation seen in the M2 subtype of AML, 4, 17, 18, 22 as well as as the t(3;21) translocation associated with myelodysplastic syndrome, chronic myelogenous leukemia in blast crisis, and therapy-related AML, 5, 21, 24 and in t(12;21) associated with acute lymphoid malignancy. 6, 27 Several myeloid leukemia-associated fusion partners have been identified for CBFA2. 17, 19, 20, 21, 24, 26 A common feature for each of these translocations is expression of the DNA binding domain of CBFA2 and disruption of the transactivating domain by the respective fusion partners. It has been shown that the DNA binding domain then has dominant negative activity in precluding normal transactivation of genes by CBFA2. 28 It is therefore possible that an inherited missense or frameshift mutation which disrupts the CBFA2 transactivating domain could lead to abnormal hematopoiesis in the pedigree. This is an attractive hypothesis, because FPD is an autosomal dominant disorder in which there is one normal and one mutant allele; the phenotype could therefore be a consequence of a dominant negative mutant. Moreover, evidence is mounting that the alternatively spliced species which contain the runt domain without the transactivation domain, may act in a similar fashion to decrease transactivation of the full length transcript (unpublished data).
The interferon ␣/␤ receptor (IFNAR1) gene encodes one of the components of the fully functional interferon ␣/␤ receptor and has been assigned to 21q22.1.
9 IFNAR1 is a member of the cytokine/growth hormone/prolactin/interferon receptor family, and is a reasonable candidate gene based on its known function. Interferon mediates a variety of effects in hematopoietic cells through interaction with its receptor, including induction of expression of interferon regulatory factor 1 (IRF-1), which has been implicated in pathogenesis of myelodys-plastic syndromes. 29 CRFB4 is located approximately 35 kb from IFNAR1 on chromosome 21. 30 Analysis of the extracellular domain indicates that CRFB4 is a typical member of the class II cytokine receptor family, which includes IFNAR, human tissue factor gene, and interferon-␥ receptor gene. Although the function and pattern of expression of the CRFB4 gene is unknown, it appears to be a gene duplication of IFNAR1 and by analogy may also play a role in hematopoiesis. In this report we describe the analysis of CBFA2, IFNAR1 and CRFB4 and show that no mutation can be identified in these genes using standard mutational analysis. Screening of the other known candidate genes and characterization and analysis of novel candidate genes which map to this locus is ongoing.
Materials and methods
Generation of lymphoblastoid cell lines and isolation of DNA and RNA Lymphoblastoid cell lines (LBCL) were established as previously described. 31 DNA was extracted from lymphoblastoid cell lines according to the manufacturer's instructions (DNA STAT 60; Tel-Test, Friendwood, TX, USA). Total RNA was extracted from lymphoblastoid cells by the acid guanidinium thiocyanate/phenol/chloroform method, 32 according to the manufacturer's instructions (RNA STAT 60; Tel-Test).
Pulsed-field gel electrophoresis and Southern hybridization
Southern blotting was performed according to standard methods 33 using LBCL DNA or genomic DNA obtained from peripheral blood as previously described. 34 Restriction endonuclease digestions were performed using 10 ng of genomic DNA and BamHI, BglII, EcoRI, PvuII or HindIII according to the manufacturer's instruction (NE BioLabs, Beverly, MA, USA). Electrophoresis was performed using a CHEF II pulsedfield apparatus (Bio-Rad, Hercules, CA, USA), and DNA was transferred to Hybond-N nylon membranes (Amersham, Arlington Heights, IL, USA) and probed with an AML1b cDNA probe containing CBFA2 nucleotides 82-956 (GenBank accession number U19601), which includes both the t(8;21) and t(3;21) breakpoint. After washing, the blot was subject to autoradiography.
Northern hybridization
Northern blotting was performed according to standard protocol 33 with modifications by Fourney and colleagues (Molecular Genetics and Carcinogenesis Laboratory, Cross Cancer Institute, Edmonton, Alberta, Canada). DNA was transferred to Hybond-N nylon membranes (Amersham) and probed with an AML1b cDNA probe containing CBFA2 nucleotides 82-956 (GenBank accession number U19601). After washing, the blot was subject to autoradiography.
Ribonuclease protection analysis
RNA was hybridized to CBFA2 riboprobes and to a ␥-actin riboprobe as an internal control of RNA integrity. Ribonuclease protection was performed as previously described. 35, 36 Single-strand conformational polymorphism (SSCP) analysis PCR-SSCP analysis was performed using a modification of a previously reported method, 37 and using PCR conditions as previously described. 38 RNA-based PCR First-strand cDNA was synthesized as previously described, 6 using 1 g of RNA and Moloney murine leukemia virus reverse transcriptase (GIBCO-BRL, Gaithersburg, MD, USA) according to the manufacturer's instructions. To amplify the CBFA2 coding region, CBFA2 sense and antisense primers were generated from the AML1b coding region (GenBank accession U19601).
Cloning and DNA sequencing cDNA amplified by PCR was purified, cloned, miniprepped and sequenced as previously described. 6 PCR products generated from exon 4 of IFNAR1 and exon 2 of CRFB4 were similarly cloned and sequenced.
Electrophoretic mobility shift assays
Cell extracts were prepared from 1 × 10 7 lymphoblastoid cells as previously described. 20 Lysates were clarified by high speed centrifugation and 20 g of cell lysate was used in EMSA. DNA-binding site selection and EMSA were performed as previously described. 20 CBFA2 antiserum was raised against a 16 amino acid peptide RIPVDASTSRRFTPPS and AML2 antiserum was raised against an 18 amino acid peptide KAQAAVGPGGRARPEVRS. RNA obtained from an affected family member (AF) and control RNA obtained from HL60, K562, an unrelated individual ('control') and JF (an unaffected family member) was subjected to ribonuclease protection analysis using CBFA2 riboprobes BH, HS and BB that span the CBFA2 gene. RNA was also hybridized to a ␥-actin probe (lower panel) to control for quantity of RNA. Probes prior to digestion with ribonuclease are shown in the lane marked 'probes'. Yeast tRNA (ytRNA) served as a control for nonspecific protection of the probe. Probe BH gives a fully protected 513-nt fragment as well as a 474-nt fragment and a 417-nt fragment corresponding to splice variants which may not contain exon 2 and exons 1 and 2, respectively. Probe HS gives a fully protected 443 bp fragment generated from the transcript containing exon 7b and a fully protected 314-bp fragment corresponding to the transcript containing exon 7a. Probe BB yields various protected fragments corresponding to various 3Ј alternative splicing. No abnormal CBFA2 transcripts could be detected in the affected family member (AF) when compared to controls. CTCAGCTGCAAAGAATGTGT a CBFA2 (AML1) oligonucleotide primer sequences used for SSCP are shown. Sequences are in the 5Ј to 3Ј orientation. Primer sequences were generated from intronic sequence except for AML1a, which lies in the 5ЈUT, and AML 7aR and 7bR, which lie in the 3ЈUT. Intronic primers do not lie over splice donor or acceptor sites. SSCP for exon 6 was generated using primers AML6/6R after nesting with AML6b/bR.
Results

Mutation analysis of the CBFA2 gene
We first analyzed the CBFA2 gene in affected and unaffected individuals by Northern and Southern blotting. There was no evidence of CBFA2 gene rearrangement by pulsed-field gel electrophoresis (data not shown). Northern blot analysis showed no abnormalities in the size or pattern of expression of CBFA2 transcripts (data not shown). Six splice variants are known to exist from work in our laboratory in cloning the TEL-CBFA2 fusion transcript, 6 and from work in other labora- Primer sequences were generated from intronic sequence except for: C1, which lies in the 5Ј untranslated region; C7, which lies in exon 6; and C7R which lies in the 3Ј untranslated region. C7 was therefore amplified from cDNA. Primers C3R and C4 lie over the splice acceptor and splice donor sites, respectively. tories 39 ( Figure 1a ). Of these, four splicing variants have potential for dominant negative activity because they lack the 3Ј transactivating domain, but retain the DNA binding domain. 39, 40 These splice variants, if present in excess of the full length transcript, could have an activity similar to the leukemia-associated fusions involving CBFA2.
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Figure 2
SSCP analysis of CBFA2. Exons 1-7 of CBFA2 were amplified from genomic DNA using flanking 32 P-labeled primers (Table 1 ) and the PCR products visualized by autoradiography after separation on MDE gels. No difference in the migration of single-stranded PCR product is appreciated between an affected (AF) and unaffected (JF) family member. Two control DNA samples (C and C1) obtained from unrelated individuals show variation in migration of amplified product from exon 1 when compared to AF and JF. Direct sequencing analysis demonstrates a polymorphism in intron 1.
A series of riboprobes which would identify all known CBFA2 splice variants were used to scan the CBFA2 coding region (Figure 1b) . Ribonuclease protection was noted to exclude variation in the relative amounts of each of the splice variants reported for the CBFA2 gene. Probe BH, which spans CBFA2 nucleotide (1-513 (GenBank accession No. U19601), gave a fully protected 513-nt fragment as well as a 474-nt fragment and a 417-nt fragment corresponding to splice variants which may not contain exon 2 and exons 1 and 2, respectively. Probe HS, which spans CBFA2 nucleotide 513-956 (GenBank accession U19601), gave a fully protected 443-bp fragment generated from the transcript containing exon 7b and a fully protected 314-bp fragment corresponding to the transcript containing exon 7a. Probe BB, which spans CBFA2 nucleotide 865-1431 (latter BamHI site present in sequence deposited by Y Groner, GenBank accession No. X79549), yields various protected fragments corresponding to various 3Ј alternative splicing. 39 No abnormal CBFA2 transcripts could be detected in the affected family member (AF) when compared to an unaffected sibling (JF) or the HL60 and K562 cell lines. There was no significant difference in the ratios of transcripts by phosphorimaging analysis except for a relative decrease in the 417-bp fragment obtained with probe BH in the affected family member, when compared to the normal sibling and cell lines. The absence of abnormal protected CBFA2 fragments in patient AF also effectively excludes a cryptic translocation involving CBFA2, as reported in t(12;21) involving TEL, a new member of the ETS family of transcription factors. 6 DNA Sequencing and SSCP analysis of the full length CBFA2 cDNA
Since point mutations could also give rise to dominant inhibitory CBFA2 gene products, we sequenced the full length coding region of the AML1b transcript. Primers were chosen from cDNA sequence spanning exons 1-8 and PCR products cloned into Bluescript were sequenced in the sense and antisense direction using the chain termination method. No point mutation, insertion or deletion was identified in sequence analysis of between 7 and 16 clones for each cDNA fragment.
In addition to sequence analysis of cDNA, SSCP analysis of CBFA2 was performed using intronic primers flanking each exon, including splice donor and acceptor sites (41; Table 1 ). There was no difference in the migration of single-stranded PCR product between affected and unaffected siblings (Figure 2 ).
Electrophoretic mobility shift analysis (EMSA)
Although no abnormalities in splicing, expression or primary sequence could be detected, EMSA was performed to document expression of a functional CBFA2 protein. Electrophoretic mobility shift analysis with a consensus CBFA2-binding site as a probe demonstrated similar binding of CBFA2 protein from cell lysates generated from an affected family member and the unaffected sibling (Figure 3 ). CBFA2 band shifts were supershifted with anti-CBFA2 antibody and competed by excess exogenous CBFA2. The amount of CBFA2 DNA binding activity in this EMSA was small, consistent with the low level of expression in lymphoblastoid cell lines as demonstrated by our laboratory and others.
42 AML2, which serves as a control (Figure 3) , is highly expressed in lymphoblastoid cell lines.
SSCP analysis of IFNAR1 and CRFB4
SSCP analysis was performed for the 11 exons of IFNAR1 and seven exons of CRFB4. Intronic primers were chosen which Electrophoretic mobility shift assay (EMSA) of CBFA2. Lymphoblastoid cell (LBC) extracts obtained from an affected (AF) and unaffected (JF) family member were analyzed by EMSA with consensus CBFA2-binding site as probe showing similar binding. Both samples were similarly supershifted with anti-CBFA2 antibody and competed by excess exogenous CBFA2 peptide. Anti-AML2 antibody was used to demonstrate specificity of probes. Ab1, antibody directed against CBFA2; Ab2, antibody directed against AML2; pep1, unlabeled, exogenous CBFA2 peptide; pep2, unlabeled exogenous AML2 peptide.
flank splice donor and acceptor sites (Tables 2 and 3 ). There is no difference in migration of amplified products between affected and unaffected individuals (Figures 4 and 5) . SSCP of IFNAR exon 4 showed a difference in migration of control sample 'C' (Figure 4) . Sequencing of amplified product demonstrated a previously reported polymorphism in exon 4 at position 19 158 with a G substitution for C leading to a leucine 168 → valine substitution. SSCP of CRFB4 showed no differences between affected and unaffected individuals but identified a novel polymorphism in exon 2 with an A → G substitution at nucleotide 182 (GenBank accession No. Z17227) yielding a lysine 47 → glutamate.
Discussion
There is evidence that myeloid leukemias, like other malignancies, result from the acquisition of serial mutations. Evidence in support of the multistep pathogenesis of AML includes: (1) clonal remission from AML; 43 (2) preleukemic syndromes, such as MDS, which progress to AML with associated acquisition of karyotype abnormalities; 44 and (3) rare families with an inherited predisposition to develop AML. 3, 45 By establishing linkage to chromosome 21q22.1-22.2 of an SSCP analysis of IFNAR1. Exons 1-11 of IFNAR1 were amplified from genomic DNA using flanking 32 P-labeled primers (Table 2 ) and the PCR products visualized by autoradiography after separation on MDE gels. No difference in the migration of singlestranded PCR product is appreciated between an affected (AF) and unaffected (JF) family member. Control DNA sample 'C' obtained from an unrelated individual shows a difference in migration of amplified product from exon 4 when compared to AF, JF and control samples 'C1' and 'C2', also obtained from unrelated individuals, consistent with a previously reported polymorphism.
autosomal dominant disorder of platelet function and number, and a striking propensity to develop AML, we have a unique opportunity to identify and characterize a gene which may be involved in the very earliest events in the multistep pathogenesis of hematologic malignancy. The physical distance of approximately 6 mB which spans the familial platelet disorder critical region is bound proximally by marker D21S1265 and distally by D21S167. Several known candidate genes map to this area including CBFA2, 4 SSCP analysis of CRFB4. Exons 1-7 of CRFB4 were amplified from genomic DNA using flanking 32 P-labeled primers (Table 3 ) and the PCR products visualized by autoradiography after separation on MDE gels. No difference in the migration of singlestranded PCR product is appreciated between an affected (AF) and unaffected (JF) family member. Control DNA sample 'C2' obtained from an unrelated individual shows a difference in migration of amplified product from exon 2 when compared to AF, JF and control samples 'C' and 'C1', also obtained from unrelated individuals, consistent with a polymorphism.
are being identified as the transcript map of chromosome 21 progresses. To identify the gene responsible for the phenotype in this pedigree, a positional cloning strategy has been undertaken, with initial efforts focused on known candidate genes. Through conventional mutational analysis, we have demonstrated that no mutation in three candidate genes CBFA2, IFNAR1 and CRFB4 can be identified in our pedigree.
The data presented are convincing that CBFA2 is not mutated in affected family members. No gross structural rearrangement was detected on Southern analysis and no abnormal patterns of expression or altered transcript size were detected on Northern analysis between affected and unaffected individuals. Ribonuclease protection assays show no differences in splicing of CBFA2 between affected and unaffected individuals and exclude a cryptic translocation affecting CBFA2.
6 CBFA2 has no point mutations as assessed by SSCP analysis of genomic DNA followed by sequencing of the full length cDNA. Finally, gel shift analysis documented expression of functional CBFA2 from affected and unaffected individuals, with no difference in protein binding to CBFA2-specific sequence, supershifting with anti-CBFA2 antibody or competition with exogenous CBFA2. We also found no evidence of mutation in the IFNAR1 or CRFB4 genes, when studied by SSCP analysis. As the sensitivity of SSCP ranges from 70 to 98% 36, [46] [47] [48] and is dependent on nucleotide sequence, fragment size and electrophoretic conditions, it is possible that a mutation in IFNAR1 or CRFB4 could have been missed using this technique. Efforts are currently underway to analyze the other known candidate genes as well as to characterize and analyze novel genes which map to this locus.
Identification and characterization of the gene responsible for causing this disorder may provide further insight into the molecular basis of platelet production and function, as well as leukemogenesis. The mutant gene responsible for the trait in this pedigree may also be involved in other familial leukemia syndromes, leukemia and hematologic abnormalities associated with Down Syndrome, and in the majority of leukemias in which there is no apparent inherited predisposition.
